Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Emergency Opioid Overdose-Counteracting Medication Approved
On Nov. 18, 2015, the U.S. Food and Drug Administration (FDA) approved the use of a nasal spray version of naloxone hydrochloride to deliver life-saving medication to those experiencing an opioid drug overdose. It is the first FDA-approved nasal spray of its kind, and will hopefully reduce the number of deaths and injuries caused by overdoses of legal opioids like hydrocodone, morphine and oxycodone, and the illegal drug heroin. These substances can so depress a victim's breathing that it becomes shallow, or may stop altogether. In the agency's press release announcing the approval, acting FDA commissioner Stephen Ostroff, M.D., said, “Combating the opioid abuse epidemic is a top priority for the FDA. We cannot stand by while Americans are dying. While naloxone will not solve the underlying problems of the opioid epidemic, we are speeding to review new formulations that will ultimately save lives that might otherwise be lost to drug addiction and overdose.” See FDA press release, “FDA moves quickly to approve easy-to-use nasal spray to treat opioid overdose,” at http://1.usa.gov/1RnclcR.
'
Emergency Opioid Overdose-Counteracting Medication Approved
On Nov. 18, 2015, the U.S. Food and Drug Administration (FDA) approved the use of a nasal spray version of naloxone hydrochloride to deliver life-saving medication to those experiencing an opioid drug overdose. It is the first FDA-approved nasal spray of its kind, and will hopefully reduce the number of deaths and injuries caused by overdoses of legal opioids like hydrocodone, morphine and oxycodone, and the illegal drug heroin. These substances can so depress a victim's breathing that it becomes shallow, or may stop altogether. In the agency's press release announcing the approval, acting FDA commissioner Stephen Ostroff, M.D., said, “Combating the opioid abuse epidemic is a top priority for the FDA. We cannot stand by while Americans are dying. While naloxone will not solve the underlying problems of the opioid epidemic, we are speeding to review new formulations that will ultimately save lives that might otherwise be lost to drug addiction and overdose.” See FDA press release, “FDA moves quickly to approve easy-to-use nasal spray to treat opioid overdose,” at http://1.usa.gov/1RnclcR.
'
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
With each successive large-scale cyber attack, it is slowly becoming clear that ransomware attacks are targeting the critical infrastructure of the most powerful country on the planet. Understanding the strategy, and tactics of our opponents, as well as the strategy and the tactics we implement as a response are vital to victory.
In June 2024, the First Department decided Huguenot LLC v. Megalith Capital Group Fund I, L.P., which resolved a question of liability for a group of condominium apartment buyers and in so doing, touched on a wide range of issues about how contracts can obligate purchasers of real property.
The Article 8 opt-in election adds an additional layer of complexity to the already labyrinthine rules governing perfection of security interests under the UCC. A lender that is unaware of the nuances created by the opt in (may find its security interest vulnerable to being primed by another party that has taken steps to perfect in a superior manner under the circumstances.
Latham & Watkins helped the largest U.S. commercial real estate research company prevail in a breach-of-contract dispute in District of Columbia federal court.